For U.S. Investors:
Westwicke
John Woolford Send Email
+1 443 213-0506
Media Contact Jasmina Alatovic
Director Global External Communications Send Email
+49 6131 9084-0
Investors & Media
Welcome to our investor page
Harnessing the immune system’s full potential to fight human disease.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Press Releases
9 April 2021
Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their C..
1 April 2021
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Throug..
31 March 2021
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine S..